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Centre Hospitalo-Universitaire Pitié-Salpêtrière, Université Pierre et Marie Curie, 75013 Paris, France, cINSERM U268,
Institut André-Lwoff, Université Paris XI, Hôpital Paul-Brousse, 94807 Villejuif, France, dMolecular Immunology,
Swiss Tropical Institute, CH-4002 Basel, Switzerland, the eService de Chirurgie Digestive, Hépato-Bilio-Pancréatique et
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Plasmodium sporozoites are transmitted through the
bite of infected mosquitoes and invade hepatocytes as a
first and obligatory step of the parasite life cycle in man.
Hepatocyte invasion involves proteins secreted from par-
asite vesicles called micronemes, the most characterized
being the thrombospondin-related adhesive protein
(TRAP). Here we investigated the expression and func-
tion of another microneme protein recently identified in
Plasmodium falciparum sporozoites, apical membrane
antigen 1 (AMA-1). P. falciparum AMA-1 is expressed in
sporozoites and is lost after invasion of hepatocytes, and
anti-AMA-1 antibodies inhibit sporozoite invasion, sug-
gesting that the protein is involved during invasion of
hepatocytes. As observed with TRAP, AMA-1 is initially
mostly sequestered within the sporozoite. Upon mi-
croneme exocytosis, AMA-1 and TRAP relocate to the
sporozoite surface, where they are proteolytically
cleaved, resulting in the shedding of soluble fragments. A
subset of serine protease inhibitors blocks the processing
and shedding of both AMA-1 and TRAP and inhibits
sporozoite infectivity, suggesting that interfering with
sporozoite proteolytic processing may constitute a valu-
able strategy to prevent hepatocyte infection.
The apicomplexan parasite Plasmodium falciparum is a
causative agent of malaria, one of the major human infectious
diseases, responsible for more than 1 million deaths per year
worldwide. Plasmodium sporozoites are transmitted through
the bite of infected mosquitoes and invade the liver of the
mammalian host, where they undergo schizogony and differen-
tiate into merozoites that subsequently invade erythrocytes
and cause disease. Blocking sporozoite invasion of hepatocytes
represents an attractive anti-malarial strategy because it
would prevent malaria symptoms and parasite transmission to
the mosquito, which both occur at erythrocytic stages. Sporo-
zoites migrate through tissues and invade target cells using
gliding motility (1), a process involving secretory vesicles called
micronemes. Upon microneme exocytosis, proteins are deliv-
ered onto the parasite surface and then redistributed from the
anterior to the posterior end of the parasite, leading to its
forward movement and penetration into a host cell (2). Only
two sporozoite microneme proteins, namely circumsporozoite
protein (CSP)1 and thrombospondin-related adhesive protein
(TRAP), have been extensively studied (3). It is quite likely,
however, that other microneme proteins are involved during
the invasion process. Recently, Florens et al. (4) reported a
comprehensive view of the proteome of P. falciparum obtained
with high resolution liquid chromatography and tandem mass
spectrometry. Interestingly, some of the proteins detected in
sporozoites had not been reported in this stage before, includ-
ing apical membrane antigen 1 (AMA-1), a microneme protein
involved in merozoite invasion of erythrocytes that is consid-
ered to be a leading candidate for inclusion in a vaccine against
erythrocytic stages of P. falciparum (5–7). Here, we have ana-
lyzed AMA-1 expression in P. falciparum sporozoites and
investigated its potential role during invasion of hepatocytes.
EXPERIMENTAL PROCEDURES
Antibodies and Inhibitors—We used previously characterized anti-P.
falciparum AMA-1 (PfAMA-1) domain III monoclonal antibody (mAb)
DV5 (8), anti-PfAMA-1 prodomain mAb 5G8 (9), anti-PfAMA-1 domain
I mAb 1F9 (9), anti-3D7 strain PfAMA-1 polyclonal rabbit IgG (10),
anti-FVO strain PfAMA-1 polyclonal rabbit IgG (11), anti-PfTRAP mAb
SSP2.2 (12), and anti-PfCSP mAb E9 (13). For liver schizont counting,
we used anti-Plasmodium HSP-70 sera obtained from mice immunized
with i72 recombinant protein (gift from D. Mattei, Institut Pasteur,
Paris, France). Secondary antibodies were fluorescein isothiocyanate-
conjugated goat anti-mouse IgG (GAM-FITC; Sigma), Alexa Fluor® 594
goat anti-rabbit IgG (GAR- Alexa Fluor® 594; Molecular Probes), per-
oxidase goat anti-mouse and peroxidase goat anti-rabbit IgG (Becton
Dickinson). Cytochalasin D (500 M stock in Me2SO) and protease
inhibitors chymostatin (2 mg/ml stock in Me2SO), pepstatin A (1 mg/ml
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stock in Me2SO), leupeptin (1 mg/ml stock in water), phenylmethylsul-
fonyl fluoride (PMSF, 100 mM stock in ethanol), and N-tosyl-L-lysine
chloromethyl ketone (TLCK, 20 mM stock in water) were from Sigma.
The peptidyl chloromethylketone N-benzyloxycarbonyl-Gly-Met-Leu-
CH2Cl (Z-GML-CH2Cl, 10 mM stock in Me2SO) was synthesized as
described (14).
Isolation of P. falciparum Sporozoites—Anopheles stephensi adult
females were infected with the NF54 strain of P. falciparum, using a
membrane-based feeder system (15). After 14–21 days, mosquitoes
were killed, and their salivary glands were aseptically dissected and
disrupted by trituration in a glass tissue grinder, and the sporozoites
were counted in a KovaSlide® chamber.
Isolation and Culture of Human Hepatocytes—Primary human hep-
atocyte cultures were prepared as described (16), with minor modifica-
tions. We used either fresh or cryopreserved hepatocytes, both suscep-
tible to infection with P. falciparum sporozoites (17, 18). In our hands,
P. falciparum sporozoite infectivity is similar in fresh and cryopre-
served hepatocytes.2 Briefly, the cells were isolated by collagenase (PAA
Laboratories) perfusion of human liver fragments, used in agreement
with the French ethical regulations, and further purified over a 40%
Percoll gradient. The hepatocytes were cryopreserved in liquid nitrogen
in fetal calf serum with 10% Me2SO; after thawing, viable hepatocytes
were purified over a 40% Percoll gradient. The hepatocytes were seeded
in eight-chamber plastic Lab-Tek slides or in 24-well culture plates
(Nalge Nunc International) coated with rat tail collagen I (Becton
Dickinson) at a density of 18  104 cells/cm2 (fresh hepatocytes) or 25 
104 cells/cm2 (cryopreserved hepatocytes). The hepatocytes were cul-
tured at 37 °C in 4% CO2, in William’s E medium (Invitrogen) supple-
mented to a final concentration of 10% fetal calf serum (Invitrogen), 2%
penicillin-streptomycin (100 stock solution; Invitrogen), 1% sodium
pyruvate (100 stock solution; Invitrogen), 1% L-glutamine (100 stock
solution; Invitrogen), 1% insulin-transferrin-selenium (100 stock so-
lution; Invitrogen). After complete cell adherence (12–24 h), the culture
medium was supplemented with 107 M dexamethasone (Sigma) and
2% Me2SO to maintain hepatocyte differentiation (19).
Culture of P. falciparum Liver Stages—Human hepatocytes were
cultured for at least 48 h before inoculation with P. falciparum sporo-
zoites (18). After the removal of medium from the culture chambers,
sporozoites in culture medium were added to the Lab-Tek wells (1  105
sporozoites/well) or plate wells (1  106 sporozoites/well) and incubated
with the hepatocytes for 3 h. The cultures were then washed and
further incubated in complete culture medium supplemented with
0.25% Me2SO. Culture medium was renewed every 2–3 days.
Reverse Transcriptase-PCR—Total RNA was purified from P. falcip-
arum NF54 sporozoites using the QIAamp RNA Blood Mini Kit (Qia-
gen), including a DNase treatment step. Reverse transcription was
performed using the ProSTAR First-Strand reverse transcriptase-PCR
kit (Stratagene). One l of cDNA was PCR amplified with the sense
primer 5-TTCAAATACTACTTTTTTAACACCG-3 and the antisense
primer 5-CTCTTTCGATTTCTTTCATTATTTC-3, by use of 40 cycles
of 45 s of denaturation at 94 °C, 45 s of annealing at 55 °C, and 60 s of
elongation at 70 °C. The resulting products (890-base pair amplicon)
were stained with ethidium bromide and run on a 1% agarose gel in Tris
acetate-EDTA buffer.
Immunofluorescence Assays—For detection of AMA-1 expression in
P. falciparum sporozoites and liver stages, air-dried sporozoites and
methanol-fixed infected hepatocyte cultures were blocked with 3% bo-
vine serum albumin in phosphate-buffered saline for 30 min and then
incubated with anti-PfAMA-1 mAb DV5 for 1 h at 37 °C, followed by
incubation with GAM-FITC and 1 g/ml DNA stain diamidino-phe-
nylindole (DAPI) for 30 min before examination by fluorescence confocal
microscopy. Surface staining was performed on nonpermeabilized
sporozoites deposited on poly-L-lysine-coated multiwell glass slides, in a
“wet” sporozoite assay (20); sporozoites were fixed in 2% paraformalde-
hyde for 20 min at room temperature, and endogenous fluorescence was
quenched with 0.1 M glycine. The parasites were blocked with 3% bovine
serum albumin in phosphate-buffered saline for 1 h and then incubated
with primary antibodies (anti-PfAMA-1 mAbs DV5, 1F9, or 5G8 or
rabbit polyclonal anti-PfAMA-1 IgG, as indicated in the figure legends)
for 2 h at 37 °C, followed by incubation with secondary antibodies
(GAM-FITC for mAbs or GAR- Alexa Fluor® 594 for rabbit IgG) and
DAPI for 1 h before examination by fluorescence microscopy.
Western Blotting and Secretion Assays—For detection of parasite
proteins in sporozoite lysates and supernatants, the parasites were
dissolved in SDS-PAGE sample buffer and incubated at 70 °C for 5 min.
The protein samples were subjected to 10% SDS-PAGE (1  105 para-
sites or equivalent/lane for AMA-1 and TRAP detection, 1  103 para-
sites or equivalent/lane for CSP detection) and transferred onto polyvi-
nylidene membranes. These were probed with primary antibodies,
followed by a peroxidase-conjugated secondary antibody, and antigens
were revealed by enhanced chemiluminescence. To analyze proteins
secreted in the parasite supernatant, sporozoites were resuspended in
medium without serum and incubated for 2 h at 37 °C in the presence
or absence of hepatocytes. The parasite suspension was then dissolved
by adding SDS-PAGE sample buffer. In some experiments, the super-
natants were separated from the sporozoites by centrifugation at
15,000  g for 5 min, and the parasite pellets and supernatants were
dissolved in SDS-PAGE sample buffer separately.
Gliding Assays—To analyze sporozoite motility, 30,000 sporozoites
were deposited on multispot glass slide wells precoated with anti-
PfCSP mAb E9 (100 g/ml 1 h at 37 °C) and incubated at 37 °C for 1 h.
The slides were then washed, and the deposited CSP trails were fixed
with 4% paraformaldehyde for 15 min. The trails were then labeled
using the anti-PfCSP mAb E9 conjugated to Alexa Fluor® 488 and
visualized under a fluorescence microscope.
Inhibition of Sporozoite Invasion Assays—To analyze sporozoite in-
vasion, triplicate hepatocyte cultures were inoculated with P. falcipa-
rum sporozoites (1  105/Lab-Tek well). After 3 h at 37 °C, the cultures
were washed, further incubated in fresh medium for 3 days, and then
fixed in methanol. Liver schizonts were stained using an anti-HSP-70
mouse serum followed by goat anti-mouse FITC conjugate and counted
under a fluorescence microscope. To determine the effects of anti-
AMA-1 antibodies on sporozoite infectivity, sporozoites were incubated
with hepatocytes in the presence of increasing concentrations of anti-
PfAMA-1 rabbit IgG. The percentage of inhibition was determined in
comparison with control rabbit IgG. To determine the effects of protease
inhibitors and cytochalasin D on sporozoite infectivity, P. falciparum
sporozoites were incubated with these inhibitors (each from a 100
stock solution diluted directly in the parasite suspension) for 5 min at
room temperature and then washed (except for cytochalasin D, the
effects of which are reversible) before inoculation onto hepatocytes. The
percentage of inhibition was determined in comparison with control
sporozoites treated with solvents alone. Inhibition results were ana-
lyzed for statistical significance using the one-way analysis of variance
followed by the Tukey multiple comparison test.
RESULTS
AMA-1 Is Expressed in P. falciparum Sporozoites—In a re-
cent analysis of P. falciparum proteome, peptides correspond-
ing to the merozoite antigen AMA-1 were identified in sporo-
zoites. Because AMA-1 had never been reported in sporozoites
before, we were interested in further characterizing its expres-
sion at this stage. Using reverse transcriptase-PCR, we could
readily detect ama-1 transcripts in salivary gland sporozoites
(Fig. 1A), thus confirming the expression of the gene at this
stage. To test whether AMA-1 protein is also present in sporo-
zoites, we performed immunofluorescence assays using the an-
ti-PfAMA-1 domain III mAb DV5 (8). All permeabilized sporo-
zoites displayed a strong fluorescence (Fig. 1B), with a bipolar
nucleus-sparing pattern similar to the immunofluorescence
pattern observed with antibodies to TRAP, also known as
sporozoite surface protein 2 (12). In contrast, surface labeling
with the anti-AMA-1 mAb showed no or very little surface
fluorescence on sporozoites (Fig. 1C). When detected, AMA-1
surface fluorescence was restricted to the apical extremity of
the sporozoites, on the same side of the nucleus as the apico-
plast, a DNA-containing organelle visualized as a DAPI-posi-
tive spot forward of the nucleus, as described in Toxoplasma
(21, 22). A similar surface fluorescence pattern was observed
using polyclonal anti-PfAMA-1 antibodies (see Fig. 5A). West-
ern blotting of protein extracts from P. falciparum sporozoites
probed with DV5 confirmed AMA-1 expression in sporozoites.
Two proteins of 83 and 66 kDa were detected in both sporo-
zoites and parasitized erythrocytes and were absent from non-
infected mosquito salivary glands (Fig. 1D). In P. falciparum
erythrocytic stages, these two bands have been shown to cor-
respond respectively to a precursor protein that contains a
prosequence and to a mature form of AMA-1 that lacks the2 O. Silvie, unpublished observations.














prosequence (23, 24). To confirm that the two bands observed in
the sporozoite lysates also correspond to the precursor and
mature forms, we performed Western blot analysis using the
anti-AMA-1 mAbs 1F9, specific for P. falciparum AMA-1 do-
main I, and 5G8, specific for AMA-1 prosequence. The mAb 5G8
recognized only the upper 83-kDa band, whereas 1F9 recog-
nized both the 83-kDa and 66-kDa proteins (Fig. 1E), thus
confirming that in P. falciparum sporozoites these two bands
correspond to the precursor and the mature form of AMA-1,
respectively. The relative amount of precursor and mature
proteins detected by Western blot varied between the different
sporozoite preparations (Fig. 1 and see Fig. 4).
AMA-1 Is Lost after Invasion of Hepatocytes and Is Re-ex-
pressed in Liver Merozoites—To assess the fate of AMA-1 after
sporozoite invasion of hepatocytes, we analyzed AMA-1 expres-
sion in primary human hepatocytes infected with sporozoites
(18). We consistently failed to detect the protein in early liver
stages by immunofluorescence assay (Fig. 2), suggesting that it
was lost after invasion of hepatocytes. AMA-1 was only re-
expressed in mature P. falciparum liver schizonts, with a punc-
tate pattern likely corresponding to nascent liver merozoites
(Fig. 2).
Anti-AMA-1 Antibodies Inhibit the Invasion of Human Hepa-
tocytes by P. falciparum Sporozoites—The expression of AMA-1
in P. falciparum sporozoites and the fact that AMA-1 was not
detected in liver schizonts until the differentiation of liver
merozoites suggested that AMA-1 could be involved in the
process of invasion of hepatocytes by sporozoites. Therefore, we
tested whether antibodies to AMA-1 could inhibit the invasion
of hepatocytes by P. falciparum sporozoites. Polyclonal IgG
raised in rabbits immunized with a recombinant AMA-1 pro-
tein from the P. falciparum 3D7 clone (10) inhibited invasion of
human hepatocytes by NF54 (homologous strain) P. falciparum
sporozoites in a concentration-dependent manner (Fig. 3). Rel-
atively high concentrations were necessary to achieve signifi-
cant inhibition, but equivalently high concentrations of IgG
from rabbits immunized with a reduced and alkylated form of
the recombinant 3D7 PfAMA-1 protein did not inhibit sporozo-
ite invasion (Fig. 3), indicating that inhibition is mediated by
antibodies directed to conformational epitopes. IgG from rab-
bits immunized with a recombinant AMA-1 from the P. falcip-
arum heterologous strain FVO (11) also inhibited NF54
P. falciparum sporozoite invasion (Fig. 3).
Upon Microneme Exocytosis, AMA-1 and TRAP Are Translo-
cated to the Sporozoite Surface and Shed as Soluble Forms after
Proteolytic Processing—Only a minority of salivary gland
sporozoites (5–10%) displayed detectable amounts of AMA-1
on their apical surface (Fig. 1C and see Fig. 5A), suggesting
that most of the protein is sequestered within the sporozoite
micronemes, as observed with TRAP (25). Upon incubation at
37 °C, which induces microneme exocytosis (26, 27), most of the
sporozoites (60–80%) expressed AMA-1 on their surface, dis-
tributed either over the whole surface or as a posterior cap (see
Fig. 5B). Sporozoite surface AMA-1 reacted with 1F9 but not
with 5G8 mAb, indicating that only the mature 66-kDa protein
translocates to the parasite surface (see Fig. 6, C and D). As
expected, both 5G8 and 1F9 mAbs labeled air-dried permeabi-
lized sporozoites (see Fig. 6, A and B) with a fluorescent pattern
similar to that observed with DV5. In P. falciparum merozoites,
AMA-1 translocates to the surface upon microneme exocytosis
and is proteolytically cleaved and shed as soluble fragments
(14, 24). To determine whether similar processing events also
occur in P. falciparum sporozoites, we analyzed by Western
blot lysates from sporozoites incubated at 37 °C. Indeed, an
AMA-1 cleavage product of 48 kDa, associated with a less
abundant product of 52 kDa, was found in lysates from sporo-
zoites incubated at 37 °C but not in lysates from sporozoites
kept at 4 °C upon isolation from mosquito salivary glands (Fig.
4A). A TRAP cleavage product was also detected in the prepa-
rations from sporozoites incubated at 37 °C, 5–10 kDa smaller
than the sporozoite TRAP, consistent with the size of the TRAP
ectodomain (Fig. 4B). Importantly, when sporozoites and su-
pernatants were analyzed separately, the cleavage products of
FIG. 1. AMA-1 is expressed in P. falciparum sporozoites. A,
reverse transcriptase-PCR analysis of ama-1 expression in P. falcipa-
rum NF54 sporozoites (spz), with () or without () reverse tran-
scriptase; Lane M, size markers; lane G, 3D7 P. falciparum genomic
DNA. The arrowhead indicates the 890-base pair amplicon. B, immu-
nofluorescence microscopy of air-dried permeabilized P. falciparum
sporozoites stained with anti-AMA-1 mAb DV5 (green) and DAPI (blue).
Bar, 5 m. C, surface immunofluorescence of P. falciparum sporozoites
stained with anti-AMA-1 mAb DV5 (green) and DAPI (blue). The sporo-
zoite nucleus is indicated with an arrow, and the apicoplast is indicated
with an arrowhead. Bar, 5 m. D, Western blotting of lysates from
noninfected mosquito salivary glands (lane sg), P. falciparum sporozoite
infected salivary glands (lane spz), and P. falciparum infected erythro-
cytes (lane e), using the anti-AMA-1 mAb DV5. E, Western blotting of
lysates from P. falciparum sporozoites using the anti-AMA-1 mAbs 1F9
and 5G8.
FIG. 2. AMA-1 is lost after invasion of hepatocytes and re-
expressed in liver merozoites. P. falciparum liver schizonts (arrow-
heads) stained with the anti-AMA-1 mAb DV5 (green) and DAPI (blue),
3, 8, or 10 days after infection of human hepatocyte cultures with
sporozoites. N, hepatocyte nucleus. Bars, 5 m.














both AMA-1 and TRAP were found only in the supernatants
not in the sporozoite pellets (Fig. 4C), demonstrating that these
products correspond to soluble proteins shed in the superna-
tant. When sporozoite supernatants were run under reducing
conditions, the AMA-1 48-kDa protein migrated as two distinct
bands, a major 48-kDa product and a minor 44-kDa product
(Fig. 4D), as observed with merozoite AMA-1 (14). The shed
TRAP product migrated as a single band under both reducing
and nonreducing conditions (data not shown). AMA-1 and
TRAP processing and shedding was observed in sporozoites
incubated at 37 °C in the absence of host cells, showing that the
protease(s) involved in this processing is (are) encoded by the
parasite. Nevertheless, incubation of sporozoites at 37 °C in
the presence of hepatocytes consistently enhanced the shedding
of AMA-1 and TRAP in the sporozoite supernatants (Fig. 4E).
AMA-1 and TRAP Are Processed by a Sporozoite Serine Pro-
tease—To further characterize the protease activities mediat-
ing AMA-1 and TRAP processing, we used a set of protease
inhibitors. Chymostatin, leupeptin, and pepstatin A had no
effect on AMA-1 and TRAP shedding (data not shown). In
contrast, two serine protease inhibitors, TLCK and Z-GML-
CH2Cl, had a profound dose-dependent inhibitory effect on
both AMA-1 and TRAP processing and shedding but had no
effect on CSP release into the supernatant (Fig. 4F). CSP was
detected as a doublet in both sporozoite pellets and superna-
tants, without any additional cleavage product detectable in
parasites incubated at 37 °C (data not shown). Strikingly,
PMSF, another serine protease inhibitor, had no significant
activity on AMA-1 or TRAP processing in sporozoites (Fig. 4G).
To further characterize the timing of processing events, we
analyzed the effects of protease inhibitors on the surface expo-
sure of AMA-1 and TRAP. Treatment with 200 M TLCK or 100
M Z-GML-CH2Cl, although profoundly inhibiting the shed-
ding of AMA-1 and TRAP, did not prevent the translocation of
AMA-1 to the sporozoite surface at 37 °C. On the contrary, the
surface exposure of AMA-1, which tended to accumulate at the
posterior end of the parasites, was rather enhanced following
treatment with these inhibitors (Fig. 5, C and D). These obser-
vations, together with the fact that AMA-1 and TRAP cleavage
products were not found associated with the sporozoite pellets,
indicate that the proteolytic processing and shedding of AMA-1
and TRAP follows the translocation of these proteins to the
parasite surface upon microneme exocytosis, suggesting that
the protease involved operates on the sporozoite surface.
Surface Translocation and Proteolytic Processing of AMA-1
and TRAP Are Not Sensitive to Cytochalasin D—Gliding mo-
tility and host cell invasion rely on a parasite actomyosin motor
that operates beneath the parasite plasma membrane and
drives the anterior-to-posterior translocation of microneme
proteins once they are released onto the parasite surface (28).
Because this actomyosin motor is blocked by the actin polym-
erization inhibitor cytochalasin D (29), we investigated the
effects of cytochalasin D on AMA-1 and TRAP processing.
Treatment of sporozoites with 5 M cytochalasin D completely
inhibited both sporozoite gliding and invasion of hepatocytes
(data not shown) but did not prevent the translocation of
FIG. 3. Anti-AMA-1 polyclonal antibodies inhibit P. falciparum
sporozoite invasion of human hepatocytes in vitro. Human hepa-
tocytes were inoculated with P. falciparum NF54 sporozoites in the
presence of IgG from rabbits immunized with a 3D7 clone PfAMA-1
recombinant protein (gray bars), with a reduced and alkylated form of
this 3D7 PfAMA-1 recombinant protein (white bar), or with a FVO
strain PfAMA-1 recombinant protein (black bar). The results are ex-
pressed as the means of the percentage of inhibition of at least two
independent experiments, each done in triplicate wells ( S.D.).
FIG. 4. Upon incubation of sporozoites at 37 °C, P. falciparum
AMA-1 and TRAP undergo proteolytic processing and shedding,
which is sensitive to a subset of serine protease inhibitors but
not to cytochalasin D. A, Western blotting of sporozoite lysates
probed with anti-AMA-1 polyclonal rabbit IgG. The arrows indicate the
48 and 52 kDa AMA-1 cleavage products, respectively. B, Western
blotting of sporozoite lysates probed with anti-TRAP mAb SSP2.2. The
arrowhead indicates the TRAP cleavage product. C, Western blotting of
pellet (P) and supernatant (SN) from sporozoites incubated at 37 °C,
probed with anti-AMA-1 polyclonal rabbit IgG or with anti-TRAP mAb
SSP2.2. The arrows and the arrowhead indicate the cleavage products
of AMA-1 and TRAP, respectively. D, Western blotting of supernatants
from sporozoites incubated at 37 °C, run under reducing (with dithio-
threitol, DTT ) or non reducing (without dithiothreitol, DTT ) con-
ditions and probed with anti-AMA-1 polyclonal rabbit IgG. E, Western
blotting of pellet (P) and supernatant (SN) from sporozoites kept at 4 °C
or incubated at 37 °C, in the absence (hep) or presence (hep) of
hepatocytes, run under reducing conditions, and probed with anti-
AMA-1 polyclonal rabbit IgG or with anti-TRAP mAb SSP2.2. The
arrow and the arrowhead indicate the 48-kDa AMA-1 and the TRAP
cleavage products, respectively. F, Western blotting of supernatants
from sporozoites treated with protease inhibitors TLCK and Z-GML-
CH2Cl (ZGML) before incubation at 37 °C. The samples were run under
reducing conditions and probed with anti-AMA-1 polyclonal rabbit IgG,
anti-TRAP mAb SSP2.2, or anti-CSP mAb E9. The arrows and the
arrowhead indicate the cleavage products of AMA-1 and TRAP, respec-
tively. G, Western blotting of supernatants from sporozoites treated
with PMSF or cytochalasin D and incubated at 37 °C. The samples were
run under reducing conditions and probed with anti-AMA-1 polyclonal
rabbit IgG or anti-TRAP mAb SSP2.2. The arrows and the arrowhead
indicate the cleavage products of AMA-1 and TRAP, respectively.














AMA-1 and TRAP to the sporozoite surface nor their subse-
quent processing upon passage at 37 °C (Figs. 4G and 5E).
However, a slight reduction of AMA-1 and TRAP shedding was
observed when sporozoites were co-incubated with hepatocytes
in the presence of cytochalasin D (Fig. 4G), probably because
cytochalasin D, by suppressing sporozoite motility, prevents
the up-regulation of microneme exocytosis induced by sporozo-
ite migration through cells (30).
Interfering with Surface Protein Processing Inhibits P. fal-
ciparum Sporozoite Infectivity—Finally, to determine whether
AMA-1 and TRAP processing is required during sporozoite
invasion of hepatocytes, we analyzed the effects of protease
inhibitors on sporozoite infectivity in vitro. Pretreatment of
sporozoites with 200 M TLCK and 100 M Z-GML-CH2Cl, both
inhibiting AMA-1 and TRAP shedding, abrogated sporozoite
gliding on glass slides (data not shown). More importantly,
treatment with TLCK and Z-GML-CH2Cl inhibited sporozoite
invasion of hepatocytes in a dose-dependent manner (Fig. 7). In
contrast, treatment of the parasites with chymostatin, leupep-
tin, pepstatin A, and PMSF, which do not prevent AMA-1 and
TRAP processing, had no significant effect on sporozoite motil-
ity and infectivity, and pretreatment of hepatocytes with the
different protease inhibitors had no effect on sporozoite inva-
sion (data not shown).
DISCUSSION
Until recently, most of the studies on hepatocyte invasion by
sporozoites focused on two sporozoite proteins, CSP and TRAP
(3). Many other proteins are expressed at the sporozoite stage
(4), with some of them being potentially involved in the inva-
sion process. Here we show that P. falciparum AMA-1, a mi-
croneme protein involved in merozoite invasion of erythrocytes
(7), is also expressed in sporozoites, thus confirming mass
spectrometry data (4). AMA-1 is lost after sporozoite invasion
and is only re-expressed in liver merozoites, suggesting that it
could play a role during invasion of hepatocytes. Indeed, anti-
FIG. 5. Protease inhibitors and cytochalasin D do not prevent
AMA-1 translocation to the sporozoite surface upon incubation
at 37 °C. Immunofluorescence analysis of AMA-1 surface exposure
using anti-AMA-1 polyclonal rabbit IgG (red) and DAPI (blue). A, un-
treated sporozoites kept at 4 °C after isolation from salivary glands. B,
untreated sporozoites incubated at 37 °C for 1 h. C, sporozoites treated
with 200 M TLCK and incubated at 37 °C for 1 h. D, sporozoites
treated with 100 M Z-GML-CH2Cl and incubated at 37 °C for 1 h. E,
sporozoites treated with 5 M cytochalasin D and incubated at 37 °C for
1h. The arrow and the arrowhead indicate the sporozoite nucleus and
the apicoplast, respectively. Bar, 5 m.
FIG. 6. Only the mature AMA-1 protein translocates to the
sporozoite surface upon incubation at 37 °C. Immunofluorescence
analysis with anti-AMA-1 mAbs 5G8 (A and C, green) or 1F9 (B and D,
green) and DAPI (blue), in air-dried permeabilized sporozoites (A and B)
or nonpermeabilized sporozoites incubated at 37 °C for 1 h (C and D).
Bar, 5 m.














bodies specific for the P. falciparum clone 3D7 AMA-1 inhibit
invasion of human hepatocytes by sporozoites of the homolo-
gous strain NF54. This inhibitory activity is directed primarily
to conformational epitopes, as indicated by the absence of neu-
tralizing activity of antibodies raised against a reduced and
alkylated form of recombinant AMA-1, as previously reported
for blood stages (10). Antibodies raised against AMA-1 of the
heterologous FVO strain also inhibit NF54 strain sporozoite
invasion, suggesting that at least part of the targeted epitopes
are conserved. Relatively high concentrations of antibodies in-
duced only partial inhibition of invasion. The neutralizing anti-
AMA-1 antibodies presumably represent a relatively small pro-
portion of the total rabbit serum IgG preparations used in these
experiments. However, AMA-1 is initially mostly sequestered
within the sporozoites and therefore may not be readily acces-
sible to antibodies, as previously reported with TRAP (25).
Much higher degrees of inhibition have been reported with
P. falciparum merozoite invasion, using the same rabbit IgG
preparations (10, 11). Interestingly, AMA-1 relocates to the
merozoite surface upon schizont rupture, so that most of the
free merozoites express AMA-1 on their surface (10, 14, 31).
These differences in AMA-1 surface exposure may explain the
higher level of inhibition seen with merozoite as compared with
sporozoite invasion. Nevertheless, the inhibition of sporozoite
invasion by anti-AMA-1 antibodies, although partial, still indi-
cates that AMA-1 could be considered as a potential candidate
to be included in a multi-stage malaria vaccine, targeting both
erythrocytic and pre-erythrocytic stages.
In P. falciparum blood stages, the mature 66-kDa AMA-1
relocates to the merozoite surface upon schizont rupture and is
proteolytically cleaved, resulting in the shedding of nearly the
whole AMA-1 ectodomain as a 48-kDa protein (24), associated
with a 44-kDa product resulting from an additional intra-
domain III cleavage (14) and with a less abundant 52-kDa
protein consistent with AMA-1 intramembrane cleavage as
described for Toxoplasma microneme proteins (32). Here we
show that similar processing events occur for AMA-1 in sporo-
zoites upon incubation at 37 °C, leading to the shedding of a
major 48-kDa protein and of less abundant products of 44 and
52 kDa. Similarly, incubation of sporozoites at 37 °C induces
TRAP processing and shedding of a fragment 5–10 kDa smaller
than full-length TRAP, consistent with the size of the TRAP
ectodomain and confirming that TRAP is released after cleav-
age of the protein, as suggested previously (26, 33). Both
AMA-1 and TRAP processing are observed in the absence of
host cells, clearly demonstrating the parasite origin of the
protease(s) involved. Still, incubation of P. falciparum sporozo-
ites at 37 °C in the presence of human hepatocytes up-regu-
lates the shedding of both AMA-1 and TRAP in the culture
supernatants. This effect is likely due to enhanced microneme
exocytosis induced by host cells (25, 30). In both merozoites (14)
and sporozoites (this study), AMA-1 translocation to the para-
site surface and its subsequent processing are not sensitive to
cytochalasin D, suggesting that microneme exocytosis in Plas-
modium is independent of the actin-dependent gliding
machinery.
Strikingly, using a set of protease inhibitors, we observed
exactly the same profile of activity on both AMA-1 and TRAP
processing. Chymostatin, leupeptin, pepstatin A, and PMSF
are ineffective, whereas TLCK inhibits in a dose-dependent
fashion the processing of both proteins. Another chloromethyl
ketone, Z-GML-CH2Cl, initially designed to inhibit merozoite
surface protein 1 processing in P. falciparum merozoites (14),
also inhibits both AMA-1 and TRAP processing. In P. falcipa-
rum merozoites, a single protease is thought to process both
AMA-1 and merozoite surface protein 1 (14), this protease
being extremely sensitive to PMSF but not to TLCK. In con-
trast, PMSF does not inhibit AMA-1 and TRAP processing in
sporozoites, whereas TLCK is very effective. This finding raises
the interesting hypothesis that the protease mediating AMA-1
and TRAP processing in sporozoites may not be the same as the
one mediating AMA-1 and merozoite surface protein 1 process-
ing in merozoites. Thus, stage-specific regulation of protein
processing may occur in P. falciparum through the expression
and/or activity of distinct proteases during the parasite life
cycle.
Treatment of P. falciparum sporozoites with the inhibitors
TLCK and Z-GML-CH2Cl, both of which irreversibly block
AMA-1 and TRAP processing, inhibits the gliding motility of
sporozoites and, more importantly, their ability to invade hu-
man hepatocytes. These results suggest that proteolytic proc-
essing of sporozoite proteins is essential for sporozoite motility
and infectivity but do not allow us to conclude that the loss of
sporozoite motility and infectivity results solely from inhibition
of TRAP and/or AMA-1 processing. It has been proposed that
posterior translocation of sporozoite TRAP provides the force
for gliding and host cell invasion via interaction with the par-
asite cytoskeleton (2). This critical role of TRAP has been
demonstrated using gene knock-out (34) or amino acid substi-
tution experiments, which have notably suggested that the
TRAP cytoplasmic tail mediates anterior to posterior redistri-
bution and posterior shedding of the protein, both functions
crucial for sporozoite gliding motility and host cell invasion
(33). Our inhibition results are consistent with this proposed
critical role of TRAP. Unlike TRAP, which is not expressed
during erythrocytic stages, AMA-1 plays a central role during
Plasmodium erythrocytic multiplication, so that ama-1 gene
knock-out is not possible (7). Alternative strategies will be
required, including conditional gene inactivation, to confirm
that AMA-1 is required during sporozoite invasion of hepato-
cytes. Further studies will be needed to identify and character-
ize the sporozoite proteases involved in AMA-1 and TRAP
processing. Even though other processing events may be af-
fected by TLCK and Z-GML-CH2Cl, our results nevertheless
demonstrate that interfering with proteolytic processing inhib-
its sporozoite infectivity and suggest that sporozoite serine
proteases may constitute potential drug targets for preventive
anti-malarial strategies.
FIG. 7. Serine protease inhibitors TLCK and Z-GML-CH2Cl in-
hibit P. falciparum sporozoite infectivity. Human hepatocytes
were inoculated with P. falciparum NF54 sporozoites pretreated with
the serine protease inhibitors TLCK and Z-GML-CH2Cl. For each in-
hibitor, the results of two independent experiments are shown and are
expressed as the mean percentages of inhibition of invasion  S.D. *,
p  0.05, as determined using the one-way analysis of variance followed
by the Tukey multiple comparison test.
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